WAVEMAN · COMPANY

NVO · Novo Nordisk A S

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

NVO

Name: NOVO NORDISK A S (NVO) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

NOVO NORDISK A S

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0000353278

CONGRESS · 2☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

684

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

2 members bought in the last year

more than 65% of Pharma & Biotech

FUNDS

684 funds added or opened last quarter

more than 98% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

2.9 days to cover · settled 2026-07-31

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

684 funds added or opened positions in the latest 13F quarter, of 1,359 holders.

2 members of Congress reported buying it this year.

2 trial completion dates slipped in the last 90 days.

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 684 funds added last quarter, 2 Congress member(s) bought in 12 months. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for NOVO NORDISK A S in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

no insider purchases or sales on record

0 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Dodge & Cox

20,397,110.0 sh

$977.8M

LOOMIS SAYLES & CO L P

18,594,352.0 sh

$891.4M

FRANKLIN RESOURCES INC

13,041,109.0 sh

$625.2M

PeakShares LLC

12,642.0 sh

$606.1M

MORGAN STANLEY

11,659,869.0 sh

$559.0M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Roundhill GLP-1 & Weight Loss ETF

$6.8M POSITION · AS OF 2026-03-31

13.1%

EuroPac International Value Fund

$11.0M POSITION · AS OF 2026-04-30

5.4%

Simplify Health Care ETF

$12.2M POSITION · AS OF 2026-03-31

5.2%

VanEck Pharmaceutical ETF

$61.9M POSITION · AS OF 2026-03-31

4.8%

Port Street Quality Growth Fund

$6.7M POSITION · AS OF 2026-03-31

4.1%

PROFUND VP EUROPE 30

$537.6K POSITION · AS OF 2026-03-31

3.4%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 448 registered trials, 128 still enrolling or running — a status change here is dated weeks before the press release

144

Phase 1

34 ACTIVE

Phase 2

11 ACTIVE

119

Phase 3

42 ACTIVE

Phase 4

3 ACTIVE

Early Phase 1

0 ACTIVE

133

Not applicable

38 ACTIVE

What changed recently

A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Ad

2026-09-05 · Active Not Recruiting → Completed

Phase 1

Weight Loss in Adults Using Semaglutide (Real-world Study)

2026-09-05 · Completion moved 2026-06-01 → 2026-06-15

—

Weight Loss in Adults Using Semaglutide (Real-world Study)

2026-09-05 · Recruiting → Completed

—

A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweig

2026-09-05 · Not Yet Recruiting → Recruiting

Phase 1

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placeb

2026-09-05 · Not Yet Recruiting → Recruiting

Phase 3

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Bloo

2026-09-02 · Recruiting → Active Not Recruiting

Phase 3

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
GROSS PROFIT	$250.3B	$245.9B	$196.5B	$148.5B
NET INCOME	$102.4B	$101.0B	$83.7B	$55.5B

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE